<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478293</url>
  </required_header>
  <id_info>
    <org_study_id>GCF-045</org_study_id>
    <nct_id>NCT03478293</nct_id>
  </id_info>
  <brief_title>iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications</brief_title>
  <official_title>A Prospective Evaluation of the Second Generation iStent Inject in Open-Angle Glaucoma Subjects on Two Preoperative Topical Ocular Hypotensive Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of
      iStent inject in eyes of subjects with primary open-angle glaucoma previously on two
      anti-glaucoma medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of
      iStent inject in eyes of subjects with primary open-angle glaucoma previously on two
      anti-glaucoma medications. Outcomes will be evaluated at 12 and 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Single (Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IOP reduction at 12 and 24 months on same number or fewer medications</measure>
    <time_frame>12 months and 24 months</time_frame>
    <description>IOP reduction at 12 and 24 months on same number or fewer medications</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Primary Open Angle Glaucoma (POAG)</condition>
  <arm_group>
    <arm_group_label>iStent inject surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent inject surgery</intervention_name>
    <description>Micro-invasive glaucoma surgery (MIGS) to implant iStent inject</description>
    <arm_group_label>iStent inject surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with primary open angle glaucoma (POAG)

          -  Subject on two ocular hypotensive medications

        Exclusion Criteria:

          -  Traumatic, uveitic, neovascular, or angle closure glaucoma

          -  Fellow eye already enrolled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Clinical Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Glaukos Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeff Wells, PharmD, MBA</last_name>
    <phone>949-367-9600</phone>
    <phone_ext>227</phone_ext>
    <email>jwells@glaukos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Ellen Giamporcaro, MS</last_name>
    <phone>949-367-0600</phone>
    <phone_ext>247</phone_ext>
    <email>jegiamporcaro@glaukos.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Ophthalmology - UNIFESP/ Hospital São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04023-62</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Maynart Tavares, MD</last_name>
      <phone>5511 5572-6443</phone>
      <email>dr.ivan.maynart@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Luci Meire Pereira da Silva, MD</last_name>
      <phone>5511 5572-6443</phone>
      <email>luci.pesquisa@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ivan Maynart Tavares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Augusto Paranhos, Jr., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulo Augusto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Teixeira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camila Netto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

